Back

Effect of sacubitril/valsartan and dapagliflozin on athletic performance; can the popular cardiac medications of recent years be used as doping agents?

31 August 2024 (13:55 - 14:05)
Organised by: Logo
Congress Presentation Part of: Drugs and exercise performance in athletes Sports Cardiology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Suha Asal

Ministry of Health Corlu State Hospital, Istanbul (Turkiye)

5 More presentations in this session

Presentation thumbnail
Heart rate response and recovery in bicycle exercise testing - reference values and association with mortality
Doctor J. Jou (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Relation between wearable heart rate monitor derived training load and cardiac adaption in endurance athletes
Mr C. Dausin (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Peak oxygen pulse response during maximal cardiopulmonary exercise testing on a treadmill: applicability analysis of the FRIEND registry prediction equation in a Brazilian healthy sample
Doctor M. Milani (Hasselt, BE)
Abstract Slides Video
Presentation thumbnail
Comparative effects of ranolazine and trimetazidine on cardiac structure and exercise capacity in a healthy rat model: a new doping agent?
Doctor S. Kilic (Tekirdag, TR)
Abstract Slides Video
Presentation thumbnail
A flattening systolic blood pressure response at the end of ramp exercise testing is not associated with all-cause mortality
Doctor A. Carlen (Linkoping, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Drugs and exercise performance in athletes
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 13:55 CET
You may be interested in
thumbnail
Congress Session
Drugs and exercise performance in athletes
thumbnail
Congress Presentation
Comparative effects of ranolazine and trimetazidine on cardiac structure and exercise capacity in a healthy rat model: a new doping agent?
thumbnail
Congress Presentation
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources